The present invention provides a compound of formula I;

The present invention provides new organic compounds of the following formula:€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒA-L1-B-C-D-L2-Ewherein A L1 B C D L2 and E are as defined in the description of the invention that are useful for treating or preventing conditions or disorders associated with DGAT1 activity particularly type 2 diabetes and pharmaceutical compositions comprising such compounds.

The invention relates to new processes for the manufacture of N-{5-[4-(4-methyl-piperazino- methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine of formula (I) new processes for the manufacture of metabolites of N-{5-[4-(4-methyl-piperazino-methyl)- benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine observed after administration of the compound to warm-blooded animals as well as to intermediates used in said processes. New starting materials as well as processes for...

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof and their preparation and use as pharmaceuticalswherein R 1 R 2 and R 3 are as defined herein. The compounds are useful for the treatment of a condition mediated by activation of the adenosine A2A receptor especially inflammatory or obstructive airways diseases. Pharmaceutical compositions comprising a purine derivative as active ingredient and a process for the preparation of these compounds.

The present invention relates to a method for preparing substituted tetrazoles compounds obtained according to this method new reactants and new tetrazole derivatives.

595234 Discloses a buffered immunogenic composition comprising at least two different meningococcal factor H binding protein (fHBP) antigens having different isoelectric points and each of the isoelectric points being between 5.0 to 7.7, a buffer with a pH range of 5.0 to 7.0 and an aluminium hydroxyphosphate adjuvant having a point of zero charge (PZC) in the range of 5.0 to 7.0, wherein he composition pH is not more than 1.2 pH units higher than the PZC of the adjuvant and wherein at least 85%...

This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[23-d]pyrimidine-6-carboxylic acid dimethylamide and salts thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[23-d]pyrimidine-6-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same.

The present invention relates to a method for preparing substituted tetrazoles compounds obtained according to this method new reactants and new tetrazole derivatives.

Abstract - 603255 Disclosed is the compound 2-(3-(cyclopropylmethyl)-2-oxo-imidazolidin-1-yl)-4-methyl-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide or a pharmaceutically acceptable salt thereof. Further disclosed is a pharmaceutical composition comprising a therapeutically effective amount of the compound 2-(3-(cyclopropylmethyl)-2-oxoimidazolidin-1-yl)-4-methyl-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide or a pharmaceutically acceptable salt thereof optionally in combination with a therapeutic...